Vaxcyte, Inc.

NasdaqGS PCVX

Vaxcyte, Inc. Market Capitalization on January 14, 2025: USD 9.74 B

Vaxcyte, Inc. Market Capitalization is USD 9.74 B on January 14, 2025, a 64.13% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.

Vaxcyte, Inc. 52-week high Market Capitalization is USD 13.93 B on October 16, 2024, which is 43.07% above the current Market Capitalization.
Vaxcyte, Inc. 52-week low Market Capitalization is USD 5.77 B on April 25, 2024, which is -40.74% below the current Market Capitalization.
Vaxcyte, Inc. average Market Capitalization for the last 52 weeks is USD 9.32 B.

Key data

Date	Market Capitalization	Share Price	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)

NasdaqGS: PCVX

Vaxcyte, Inc.

CEO	Mr. Grant E. Pickering M.B.A.
IPO Date	June 12, 2020
Location	United States
Headquarters	825 Industrial Road
Employees	254
Sector	Health Care
Industries Vaccines Biotechnology Pharmaceuticals

Description

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Key trends

Past 5 years